Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

Biocon Rumours of Oral Insulin Deal Push Up Stock 10%


Biocon has been rumoured to have serious developments in its oral insulin product, and in talks with a few large pharma companies to license the product. This supposedly involves a big upfront payment and some kind of investment by these companies into Biocon.

The stock is up about 10% on the news.



Biotech stocks are useful to own if you believe in their capability to develop drugs or do deals. Biocon makes “biosimilars” of insulin, and they own IP in the oral insulin space (as opposed to injected insulin which is the standard today) The result of investing in such companies is often one-shot, where the stock sputters along for a long time, but when they do a deal it gets a massive surge of income. (And the stock goes up big).

While I’ve invested in Biocon, it’s mostly been for the fact that I believe they will make such deals, not because of their biosimilar manufacturing (which is more bread-and-butter). The stock price increase, though, is just on speculation, so I’m not really confident this deal happens. In fact, the Biocon CEO, Kiran Majumdar-Shaw, just tweeted that this is “irresponsible”.


So what’s it going to be? Real news or profit-taking rumour?

Disclosure: Long the stock.


Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial